Skip to main content
. 2017 Nov 21;37(6):BSR20171039. doi: 10.1042/BSR20171039

Figure 6. Sp-8-Br-cAMPS inhibits cell migration and proliferation in breast cancer cell lines.

Figure 6

(A) Boyden chamber assay analysis of the effects of 60 µM Sp-8-Br-cAMPS on breast cancer cell migration in MCF7 (n=4), MDA231 (n=4) and SKBR3 (n=4) cells. Boyden chamber assay was performed over a 3-h incubation period to allow cell migration across the polycarbonate membrane; scale bars = 250 μm. (B) Alamar Blue assay analysis of the effects of 60 µM Sp-8-Br-cAMPS on MCF7 (n=4), MDA231 (n=4) and SKBR3 (n=4) cell proliferation. Cells were starved in serum-free medium overnight prior to drug treatment. (C) Alamar Blue assay analysis of the effects of a two-phase treatment with 60 µM Sp-8-Br-cAMPS on MCF7 (n=5), MDA231 (n=5) and SKBR3 (n=5) cell proliferation. Cells were starved in serum-free medium overnight prior to drug treatment. Cells were subsequently treated with 60 µM Sp-8-Br-cAMPS for 1 h prior to treatment replacement with a fresh 60 µM Sp-8-Br-cAMPS solution and a further 24-h incubation. Alamar Blue assays were performed by incubating cells in 10% AlamarBlue® dye (diluted in serum-free medium) for 4 h. Mean % migration and mean % proliferation values were compared using an unpaired t-test. Mean values presented ± SEM; **P≤0.01, ***P≤0.001.